- Design
- Systematic review with pairwise and network meta-analysis of RCTs
- Population
- 29 trials; 13,387 methotrexate-naive adults with early RA
- Primary outcome
- DAS28 remission at 6 months
- Effect
- b/tsDMARD + MTX vs MTX: RR 1.62 (95% CI 1.39 to 1.89)
A systematic review and meta-analysis in Rheumatology, published on 1 October, pooled 29 randomised trials and 13,387 methotrexate-naive adults with early rheumatoid arthritis, comparing initial biologic or targeted synthetic DMARDs, with or without methotrexate, against methotrexate alone.
Adding a biologic or targeted drug to methotrexate from the start increased DAS28 remission at six months (RR 1.62, 95% CI 1.39 to 1.89), with similar gains at three and twelve months and on CDAI remission and ACR50. Every drug class combined with methotrexate outperformed methotrexate alone. The benefit was larger in trials with higher baseline disease activity and more rheumatoid factor-positive patients. As monotherapy, only tocilizumab and JAK inhibitors beat methotrexate at class level.
This does not overturn current EULAR and ACR guidance, which starts with methotrexate and escalates if targets are not met; the meta-analysis compares remission only, not long-term safety, cost or what happens with rapid escalation. JAK inhibitors also carry cardiovascular and malignancy cautions in older patients with risk factors. In India, where most patients pay for biologics themselves, cost is decisive.
The practical change is speed. For a patient with high disease activity and positive rheumatoid factor, waiting six months on methotrexate alone forgoes remission that combination therapy could have delivered. Reviewing at three months and escalating promptly if the target is not met captures much of that benefit while staying within guidelines.
- Start with methotrexate as guidelines recommend, but review response at three months, not six.
- Escalate promptly to a biologic or targeted drug if the target is missed, especially in high-activity, RF-positive disease.
- Consider tocilizumab or a JAK inhibitor if methotrexate cannot be used and monotherapy is needed.
- Weigh JAK inhibitor cardiovascular and malignancy cautions in older patients and smokers.
- Discuss cost openly; in India it often decides what is possible.
Why it matters
The remission gap between methotrexate alone and combination therapy is large enough that slow escalation has a real cost.
Don't overread it
Guidelines have not changed; this pooled remission data does not address long-term safety or cost.
The statistics, in plain English
An RR of 1.62 means about 60% more patients reached remission with combination therapy. The subgroup findings on disease activity and rheumatoid factor come from comparing trials, not patients, so they are weaker than the main result.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free